Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, gives an update on the 12-year follow-up results of the SOFT (NCT00066690) and TEXT (NCT00066703) trials, which investigated adjuvant endocrine therapy for premenopausal women with hormone-receptor-positive (HR+) early breast cancer. These results reported that the use of ovarian function suppression (OFS) with either tamoxifen or exemestane vs. tamoxifen alone for 5 years results in persistent long term reduction in risk of distant recurrence, with the reduction being greatest in patients who received exemestane. The use of OFS was also reported to reduce risk of death in the long-term. Dr Regan emphasises how important further follow-up of these trials is, in part due to the persistent risk of recurrence in these patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

свернуть